Literature DB >> 17654565

Lower urinary tract symptoms (LUTS) and bladder afferent activity.

Naoki Yoshimura1.   

Abstract

AIMS: Dysregulation of bladder afferent activity and detrusor smooth muscle behavior leads to a constellation of lower urinary tract symptoms (LUTS), which includes overactive bladder (OAB). Current treatments for LUTS are poorly tolerated and may be associated with substantial adverse effects.
METHODS: Major advances in the understanding of bladder neuroanatomy and the role of bladder afferent pathways in symptom generation suggest a range of targets for new therapeutic agents.
RESULTS: A sensory role for urothelial and suburothelial structures has been established, as well as a cascade of afferent bladder signaling involving the bladder epithelium and detrusor muscle. Numerous inhibitory and stimulatory neurotransmitters and chemical mediators interact with a variety of specialized receptors and participate in signal transduction leading to wider neuroactivation. The blockade of muscarinic receptors, possibly mediated by muscarinic 2 (M(2)) receptors residing in the urothelium, has been shown to affect bladder afferent fibers, challenging the traditional concept that antimuscarinic therapy involves M(3) receptor-mediated effects on detrusor smooth muscle. The propagation of impulses to spinal and higher centers utilizes axonal fiber tracts remarkable for their morphologic and functional plasticity as bladder function becomes increasingly disordered.
CONCLUSIONS: These findings suggest that the etiology of LUTS includes enhanced, dysregulated, and perhaps maladaptive sensory signaling arising from numerous pelvic locales, including the most superficial epithelium of the bladder. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17654565     DOI: 10.1002/nau.20487

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  16 in total

1.  A new look at detrusor underactivity: impaired contractility versus afferent dysfunction.

Authors:  Anne M Suskind; Phillip P Smith
Journal:  Curr Urol Rep       Date:  2009-09       Impact factor: 3.092

2.  Functional and morphological properties of pericytes in suburothelial venules of the mouse bladder.

Authors:  Hikaru Hashitani; Retsu Mitsui; Yuki Shimizu; Ryuhei Higashi; Keiichiro Nakamura
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 3.  Electrical stimulation for neuroregeneration in urology: a new therapeutic paradigm.

Authors:  Brian M Balog; Kangli Deng; Vinod Labhasetwar; Kathryn J Jones; Margot S Damaser
Journal:  Curr Opin Urol       Date:  2019-07       Impact factor: 2.309

4.  Differential roles of M2 and M3 muscarinic receptor subtypes in modulation of bladder afferent activity in rats.

Authors:  Yoshihiro Matsumoto; Minoru Miyazato; Akira Furuta; Kazumasa Torimoto; Yoshihiko Hirao; Michael B Chancellor; Naoki Yoshimura
Journal:  Urology       Date:  2010-02-13       Impact factor: 2.649

5.  Expression of transient receptor potential vanilloid 4 and effects of ruthenium red on detrusor overactivity associated with bladder outlet obstruction in rats.

Authors:  Kang Jun Cho; Eun Young Park; Hyo Sin Kim; Jun Sung Koh; Joon Chul Kim
Journal:  World J Urol       Date:  2013-05-23       Impact factor: 4.226

6.  Myocardin and microRNA-1 modulate bladder activity through connexin 43 expression during post-natal development.

Authors:  Masaaki Imamura; Yoshio Sugino; Xiaochun Long; Orazio J Slivano; Nobuyuki Nishikawa; Naoki Yoshimura; Joseph M Miano
Journal:  J Cell Physiol       Date:  2013-09       Impact factor: 6.384

Review 7.  Bladder pain syndrome/interstitial cystitis: a sense of urgency.

Authors:  Philip M Hanno; Chris R Chapple; Linda D Cardozo
Journal:  World J Urol       Date:  2009-12       Impact factor: 4.226

8.  Local activation of cannabinoid CB₁ receptors in the urinary bladder reduces the inflammation-induced sensitization of bladder afferents.

Authors:  Jean-Sébastien Walczak; Fernando Cervero
Journal:  Mol Pain       Date:  2011-05-09       Impact factor: 3.395

9.  Expression of caveolin-1 in rat urinary bladder with cyclophosphamide-induced cystitis.

Authors:  Sun-Ouck Kim; Seung Hee Song; Seung-Chul Lee; Kyung A Cho; Ho Song Yu; In Sang Hwang; Eu Chang Hwang; Dongdeuk Kwon
Journal:  Int Neurourol J       Date:  2012-12-31       Impact factor: 2.835

10.  Intravesical resiniferatoxin for the treatment of storage lower urinary tract symptoms in patients with either interstitial cystitis or detrusor overactivity: a meta-analysis.

Authors:  Changcheng Guo; Bin Yang; Wenyu Gu; Bo Peng; Shengqiang Xia; Fengqiang Yang; Deyi Wen; Jiang Geng; Yuanyuan Zhang; Junhua Zheng
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.